Xiaoqing Yu

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.

Journal: Cancer discovery

Published: August 02, 2025

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.

Journal: International journal of cancer

Published: December 04, 2023

Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

Journal: Cancer medicine

Published: May 20, 2023

Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China.

Real-world treatment and prognostic factors for survival in ALK+ non-small cell lung cancer (NSCLC) patients with brain metastases in China.

Journal: Thoracic cancer

Published: September 18, 2022

The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.

The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.

Journal: Cancer medicine

Published: August 01, 2022

A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.

A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.

Journal: Journal of translational medicine

Published: September 12, 2021

Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.

Integrated genomic and DNA methylation analysis of patients with advanced non-small cell lung cancer with brain metastases.

Journal: Molecular brain

Published: August 30, 2021

Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.

Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.

Journal: Thoracic cancer

Published: June 11, 2021

The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.

The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.

Journal: Translational cancer research

Published: February 03, 2021

Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.

Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.

Journal: Translational lung cancer research

Published: January 25, 2021

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.

Journal: International journal of cancer

Published: December 15, 2020

Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1  Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis

Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1  Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Published: August 11, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026